Login
$SCYX
$2.90 -$0.31 (9.66%) Live

$SCYX 8-K SEC Filings

Filed On Filing
28 Sep 2026 8-K: Entry into a Material Definitive Agreement; Regulation FD Disclosure

BARDA partnership accelerates development of SCY-247 as a potential therapy for the treatment and prevention of serious invasive fungal infections, addressing a critical public health need

22 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

JERSEY CITY, N.J., September 22, 2026 – SCYNEXIS, Inc. (NASDAQ: SCYX) (“SCYNEXIS” or the “Company”), a clinical-stage biotechnology company dedicated to advancing innovative solutions for severe rare diseases, today announced the appoint...

10 Sep 2026 8-K: Departure/Election of Directors or Officers; Compensation; Other Events

Accomplished biopharmaceutical finance executive brings extensive experience driving capital markets activities, strategic transactions, and growth across public companies.

26 Jun 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year; Submission of Matters to a Vote of Security Holders +1 more

We have acted as counsel to SCYNEXIS, Inc., a Delaware corporation (the “Company”), in connection with the filing by the Company of a Registration Statement on Form S-3 (the “Registration Statement”) with the Securities and Exchange Comm...

29 May 2026 8-K: Amendments to Articles/Bylaws; Change in Fiscal Year

SCYNEXIS, Inc., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “Corporation”), hereby certifies that:

22 May 2026 8-K: Submission of Matters to a Vote of Security Holders; Other Events

A special meeting of the stockholders of SCYNEXIS, Inc. (the “Company”) was held on May 19, 2026 (the “Special Meeting”). Proxies for the Special Meeting were solicited by the Board of Directors of the Company pursuant to Section 14(a) o...

20 Apr 2026 8-K: Departure/Election of Directors or Officers; Compensation

On April 16, 2026, Steven C. Gilman, a member of the Board of Directors (the “Board”) of SCYNEXIS, Inc. (the “Company”), notified the Company of his intent to retire as a member of the Board and therefore not stand for reelection at the ...

31 Mar 2026 8-K: Regulation FD Disclosure

Exhibit 99.1 Advancing innovative solutions for severe rare diseases Corporate Deck March 2026

31 Mar 2026 8-K: Entry into a Material Definitive Agreement; Unregistered Sales of Equity Securities +2 more

This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of March 30, 2026, by and among SCYNEXIS, Inc., a Delaware corporation (the “Company”), and each of the entities listed on Exhibit A attached to this Agreement (each, an “...

31 Mar 2026 8-K: Entry into a Material Definitive Agreement; Completion of Acquisition or Disposition of Assets +1 more

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)

15 Oct 2025 8-K: Entry into a Material Definitive Agreement

On October 14, 2025, SCYNEXIS, Inc. (“SCYNEXIS”) and GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”) entered into a binding memorandum of understanding (the “Binding 2025 MOU”) for amendment to the exclusive license agreeme...

01 Jul 2025 8-K: Submission of Matters to a Vote of Security Holders

On June 25, 2025, SCYNEXIS, Inc. held its 2025 Annual Meeting of Stockholders. The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final tally of the number of votes cast: (a) for or withh...

26 Jun 2025 8-K: Notice of Delisting or Failure to Satisfy a Listing Rule

On June 20, 2025, SCYNEXIS, Inc. (“SCYNEXIS”) received a letter from the Listing Qualifications Department staff (the “Staff”) of the Nasdaq Stock Market (“Nasdaq”) notifying SCYNEXIS that, for the last 30 consecutive business days, the ...

06 Nov 2024 8-K: Other Events

Cantor Fitzgerald & Co. 110 East 59th StreetNew York, NY 10022

10 Sep 2024 8-K: Regulation FD Disclosure

A dynamic force in the fight against infectious disease September 2024

20 Jun 2024 8-K: Submission of Matters to a Vote of Security Holders

On June 19, 2024, SCYNEXIS, Inc. held its 2024 Annual Meeting of Stockholders. The following is a brief description of each matter voted upon at the Annual Meeting, as well as the final tally of the number of votes cast: (a) for or withh...

28 Mar 2024 8-K: Results of Operations and Financial Condition

SCY-247’s IND-enabling activities continue to advance with initiation of Phase I anticipated in the second half of 2024

05 Jan 2024 8-K: Regulation FD Disclosure

A dynamic force in the fight against infectious disease January 2024

02 Jan 2024 8-K: Entry into a Material Definitive Agreement

On December 26, 2023, SCYNEXIS, Inc. (“SCYNEXIS”) and GlaxoSmithKline Intellectual Property (No. 3) Limited (“GSK”) entered into a binding memorandum of understanding (“Binding MOU”) for amendment to the exclusive license agreement betwe...

02 Oct 2023 8-K: Other Events

On September 25, 2023, SCYNEXIS, Inc. (the “Company”) disclosed that, after becoming aware of a risk of potential cross-contamination during the manufacture of ibrexafungerp, the Company was recalling BREXAFEMME® (ibrexafungerp tablets) ...

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support